In the present day scenario, even if many advances in diabetic therapy have been
sought, but it is still in its formative years. Nanotechnology has brought a range of novel
promises into biological discovery and medical practice. Nanoparticulate drug delivers have
revolutionized drug delivery, allowing therapeutic agents to be selectively targeted for organs,
tissues and cell specific levels, minimizing exposure of healthy tissues to drugs. Keeping
all the views in mind, Glimepiride loaded PLGA nanoparticles (NPs) were prepared by
the solvent evaporation method. Physicochemical characterization of NPs included dynamic
laser spectroscopy and atomic force microscopy confirmed the mean particle diameter of NPs was ~300 nm
with spherical morphology. Fourier transform infrared spectroscopy and differential scanning calorimetry
analysis depicted no interaction between the drug and polymer in formulation. Drug encapsulation efficiency
was found to be ~55 % and it released from NPs in a sustained manner. Blood glucose level of glimepiride
loaded NPs treated to diabetic rats was reduced significantly to normal level compared with native drug
treated group. Thus, this system could facilitate to achieve a sustained formulation resulting in reduced dose
frequency and improved patient compliance for type-2 diabetes mellitus management.
Keywords: Diabetes, drug delivery, Glimepiride, Nanoparticles, PLGA nanoparticles, Release kinetics.
Rights & PermissionsPrintExport